Explore important resources that can help you during your treatment

Starting a new treatment can bring new questions

A range of resources are available to help you get started and stay on track with MIMRYLO™ (rusfertide).

Patient Brochure

A comprehensive summary guide for you and your loved ones to learn more about MIMRYLO, including information on clinical study results, side effects, and support resources.

Download the PDF

Dosing & Administration Guide

Explore step-by-step guidance for dosing, preparing, and administering MIMRYLO.

Download the PDF

Step-by-Step Injection Guide

Injection information so you can start self-administering MIMRYLO.

Download the PDF

MIMRYLO Patient Support Flashcard

Extra support resources for you, like access to Nurse Support Services and enrollment assistance.

Download the PDF

IMPORTANT SAFETY INFORMATION

Expand

Before using MIMRYLO, tell your healthcare provider about all of your medical conditions, including if you:

are pregnant or plan to become pregnant. MIMRYLO may harm your unborn baby.
Females who are able to become pregnant:
- Your healthcare provider may do a pregnancy test before you start treatment with MIMRYLO.
- Use effective birth control (contraception) during treatment and for at least 30 days after the final dose of MIMRYLO.
- Tell your healthcare provider right away if you become pregnant or think that you may be pregnant during treatment with MIMRYLO.
- Stop taking MIMRYLO if you become pregnant.
are breastfeeding or plan to breastfeed. It is not known if MIMRYLO passes into your breast milk. Do not breastfeed during treatment with MIMRYLO and for 30 days after the final dose of MIMRYLO. Talk to your healthcare provider about the best way to feed your baby during this time.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

What are the possible side effects of MIMRYLO?

MIMRYLO may cause serious side effects, including:

New or worsening increased blood platelets (thrombocytosis). MIMRYLO may increase blood platelet counts. Your healthcare provider will do blood tests when you start and during treatment with MIMRYLO to check your platelet counts.
Injection site reactions. MIMRYLO may cause injection-site reactions such as redness, itching, pain, swelling, bruising, hardening at the injection site, and irritation. If you get an injection site reaction, apply ice packs, steroid cream, or take medicines as needed to treat injection site pain and swelling.

Your healthcare provider may change your dose or stop treatment with MIMRYLO if you have side effects.

The most common side effects of MIMRYLO are:

injection site reactions
low red blood cell count (anemia)

These are not all of the possible side effects of MIMRYLO. Call your doctor for medical advice about side effects. You may report side effects to Takeda at 1-844-662-8532 or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see Patient Information in the MIMRYLO (rusfertide) full Prescribing Information.

IMPORTANT SAFETY INFORMATION

Before using MIMRYLO, tell your healthcare provider about all of your medical conditions, including if you:

are pregnant or plan to become pregnant. MIMRYLO may harm your unborn baby.
Females who are able to become pregnant:
- Your healthcare provider may do a pregnancy test before you start treatment with MIMRYLO.
- Use effective birth control (contraception) during treatment and for at least 30 days after the final dose of MIMRYLO.
- Tell your healthcare provider right away if you become pregnant or think that you may be pregnant during treatment with MIMRYLO.
- Stop taking MIMRYLO if you become pregnant.
are breastfeeding or plan to breastfeed. It is not known if MIMRYLO passes into your breast milk. Do not breastfeed during treatment with MIMRYLO and for 30 days after the final dose of MIMRYLO. Talk to your healthcare provider about the best way to feed your baby during this time.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

What are the possible side effects of MIMRYLO?

MIMRYLO may cause serious side effects, including:

New or worsening increased blood platelets (thrombocytosis). MIMRYLO may increase blood platelet counts. Your healthcare provider will do blood tests when you start and during treatment with MIMRYLO to check your platelet counts.
Injection site reactions. MIMRYLO may cause injection-site reactions such as redness, itching, pain, swelling, bruising, hardening at the injection site, and irritation. If you get an injection site reaction, apply ice packs, steroid cream, or take medicines as needed to treat injection site pain and swelling.

Your healthcare provider may change your dose or stop treatment with MIMRYLO if you have side effects.

The most common side effects of MIMRYLO are:

injection site reactions
low red blood cell count (anemia)

Please see Patient Information in the MIMRYLO (rusfertide) full Prescribing Information.